Invivyd IVVD
NASDAQ IVVD
$0.83 +0.00 (+0.00%)
At close: Sep 4, 2026 · 4:00 PM EDT

Invivyd (IVVD) Profit After Tax (2021 - 2026)

Invivyd's (IVVD) quarterly Profit After Tax came in at -$44.4 million in Q2 2026, down 202.28% on a YoY basis from $43.4 million in Q2 2025, and down 301.02% quarter-over-quarter from -$11.1 million in Q4 2025.

Analysis

Invivyd (IVVD) Profit After Tax (2021 - 2026) Analysis & Trends

Invivyd (IVVD) has reported Profit After Tax for 6 consecutive years, with -$44.4 million the latest figure, recorded in Q2 2026.

  • For the quarter ending Q2 2026, Profit After Tax fell 202.28% year-over-year to -$44.4 million; the trailing twelve-month figure through Jun 2026 stood at -$80.6 million (up 26.81% YoY), and the FY2025 full-year result was -$52.5 million, up 69.09% from the prior year.
  • Profit After Tax retreated to -$44.4 million in Q2 2026 per IVVD's latest filing, from -$11.1 million in the prior quarter.
  • Across five years, Profit After Tax topped out at -$10.5 million in Q3 2025 and bottomed at -$100.7 million in Q1 2022.
  • Historically, Profit After Tax has averaged -$41.6 million across 5 years, with a median of -$44.4 million in 2026.
  • The sharpest annual moves came in 2025 and 2026: Profit After Tax soared 82.76% in 2025, then plunged 202.28% in 2026.
  • Over 5 years, Profit After Tax stood at -$44.8 million in 2022, then sank by 64.27% to -$73.7 million in 2023, then surged by 74.97% to -$18.4 million in 2024, then surged by 39.96% to -$11.1 million in 2025, then sank by 301.02% to -$44.4 million in 2026.
  • According to Business Quant data, Profit After Tax over the past three periods registered -$44.4 million, -$11.1 million, and -$10.5 million for Q2 2026, Q4 2025, and Q3 2025 respectively.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) PAT (Qtr)
1 Amgen 236.37 Bn 222.38 Bn 7.24 Bn 2.38 Bn
2 Gilead Sciences 187.38 Bn 184.12 Bn 6.22 Bn -10.50 Bn
3 Vertex Pharmaceuticals 138.36 Bn 130.51 Bn 2.84 Bn 1.10 Bn
4 Regeneron Pharmaceuticals 85.09 Bn 77.10 Bn 3.93 Bn 1.30 Bn
5 Argenx Se 63.93 Bn 58.75 Bn 1.37 Bn 472.00 Mn
6 Moderna 58.07 Bn 52.94 Bn 52.00 Mn -782.00 Mn
7 Alnylam Pharmaceuticals 35.59 Bn 32.28 Bn 992.69 Mn 164.49 Mn
8 Biogen 32.63 Bn 31.34 Bn 1.96 Bn 97.50 Mn
9 Insmed 27.57 Bn 26.41 Bn 358.27 Mn -16.62 Mn
10 Invivyd 244.65 Mn 84.57 Mn 13.01 Mn -44.39 Mn
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 -44.39 Mn
Dec 31, 2025 -11.07 Mn
Sep 30, 2025 -10.47 Mn
Jun 30, 2025 -14.69 Mn
Mar 31, 2025 -16.29 Mn
Dec 31, 2024 -18.44 Mn
Sep 30, 2024 -60.75 Mn
Jun 30, 2024 -47.25 Mn
Mar 31, 2024 -43.50 Mn
Dec 31, 2023 -73.65 Mn
Sep 30, 2023 -39.44 Mn
Jun 30, 2023 -50.23 Mn
Mar 31, 2023 -35.32 Mn
Dec 31, 2022 -44.84 Mn
Sep 30, 2022 -45.09 Mn
Jun 30, 2022 -50.99 Mn
Mar 31, 2022 -100.67 Mn
Dec 31, 2021 -83.04 Mn
Sep 30, 2021 -60.38 Mn
Jun 30, 2021 -44.67 Mn